Active Stocks Buzzers: QUALCOMM (QCOM), AbbVie Inc (ABBV)

0
759

QUALCOMM, Inc. (NASDAQ:QCOM)

Stock’s Trading Stats:

QUALCOMM, Inc. (NASDAQ:QCOM) is trading up with a percentage change of 0.59% and is at $50.82 right now. The Company’s market capitalization stands at $72.34 Billion in the current trading Session whereas, its outstanding shares are 1.47 Billion.

Recent Press Release:

QUALCOMM, Inc. (QCOM) on May 3, 2016 declared at the Embedded Vision Summit in Santa Clara, Calif., that its partner, Qualcomm Technologies, Inc., is offering the first deep learning software development kit (SDK) for devices powered by Qualcomm® Snapdragon™ 820 processors. The SDK, called the Qualcomm Snapdragon Neural Processing Engine, is powered by the Qualcomm® Zeroth™ Machine Intelligence Platform and is optimized to utilize Snapdragon’s heterogeneous compute capabilities to provide OEMs a powerful, energy efficient platform for delivering intuitive and engaging deep learning-driven experiences on device. This SDK is the most recent software addition to Snapdragon 820 and demonstrates Qualcomm Technologies’ continued leadership by adding value for our customers to the Snapdragon portfolio.

Qualcomm Technologies, with the introduction of the Snapdragon Neural Processing Engine, is the first mobile SOC provider to offer a deep learning toolkit optimized for mobile.  This SDK will allow OEMs to run their own neural network models on Snapdragon 820 devices such as smart phones, security cameras, automobiles and drones, all without a connection to the cloud. Common deep learning user experiences that can be realized with the SDK are scene detection, text recognition, object tracking and avoidance, gesturing, face recognition and natural language processing.

The Zeroth Machine Intelligence Platform is a Snapdragon-optimized software platform designed for mobile machine learning. Zeroth technology presently drives visual intelligence software such as Snapdragon Scene Detect and advanced malware detection software found in Snapdragon Smart Protect.

AbbVie Inc (NYSE:ABBV)

Stock’s Trading Stats:

AbbVie Inc (NYSE:ABBV) is surging 0.57% percent and is at $61.36 in the Real-Time trading session. The stock’s market capitalization stands at $98.94 Billion with outstanding shares of 1.61 Billion.

Recent Press Release:

AbbVie Inc (ABBV) on April 29, 2016 declared that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion in favor of the use of IMBRUVICA (ibrutinib) for the treatment of adult patients with formerly-untreated chronic lymphocytic leukemia (CLL) in the European Union (EU). The positive CHMP recommendation follows the March 4, 2016 U.S. Food and Drug Administration (FDA) approval of IMBRUVICA for the first-line treatment of patients with CLL.1 If approved by the European Commission (EC), this would be the fifth treatment indication for IMBRUVICA in the EU to date.

CLL is a chronic disease, and the prevalence rate in Europe among men and women is about 5.87 and 4.01 cases per 100,000 persons per year, respectively.2  An expansion of the CLL indication in Europe would mean a larger number of CLL patients, in addition to those with the genetic mutations del 17p or TP53, could initiate their treatment with a safe and effective oral alternative option to chemotherapy, rather than having to wait until they have become relapsed or refractory on another treatment option.

IMBRUVICA is jointly developed and commercialized in the U.S. by Pharmacyclics LLC, an AbbVie company and Janssen Biotech, Inc. In Europe, Janssen-Cilag International NV (Janssen) holds the marketing authorization and its associates market IMBRUVICA in EMEA (Europe, Middle East, Africa), in addition to the rest of the world. IMBRUVICA is already approved in Europe to treat adult patients with relapsed or refractory mantle cell lymphoma (MCL), adult patients with CLL who have received at least one prior therapy or who have del 17p or TP53 mutations, and adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy, or as a first-line treatment for WM patients unsuitable for chemo-immunotherapy. The EC will review the CHMP opinion and is predictable to render a final decision on the use of IMBRUVICA for formerly untreated patients with CLL later this year.